Abstract
Background: The histamine H2 receptor antagonist ranitidine is US FDA-approved for the treatment of gastroesophageal reflux disease and healing of erosive esophagitis in children ≥1 month of age. A low-dose strength of ranitidine is now available in a citrus-flavored 25mg effervescent tablet (dissolved in 5mL of water); this formulation was developed to facilitate use in infants and smaller children. Ranitidine syrup is available in a peppermint-flavored 15 mg/mL formulation.
Objective: To compare taste preferences for ranitidine (Zantac®) syrup and ranitidine effervescent tablets dissolved in water (Zantac® EFFERdose®) in healthy children aged 4–8 years and their adult caregivers.
Study Design and Methods: A randomized, single-blind, crossover, taste test trial was conducted in 102 children and 102 parents/legal guardians. All subjects received a single 45mg dose of each formulation. After tasting both preparations children were asked: “Now that you have tasted both medicines, which one of these medicines do you think tastes better?” Adults were asked four questions to assess whether they would administer the medication to the children.
Results: Seventy-one percent (72/102) of the children preferred the taste of the ranitidine effervescent tablets compared with 29% (30/102) who preferred the syrup (p < 0.001). The majority of adults (71%) responded that they would prefer to administer the effervescent formulation based on taste. Adverse events consistent with product labeling were mild and were reported in four children and three adults: headache (n = 3), drowsiness (n = 1), abdominal pain/cramps (n = 2), and bloating/gas (n = 1).
Conclusion: The taste of the ranitidine effervescent formulation dissolved in water is preferred over the ranitidine syrup. Better taste acceptance may facilitate ease of administration and compliance in pediatric patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement by the publisher.
References
Rudolph CD. Supraesophageal complications of gastroesophageal reflux in children: challenges in diagnosis and treatment. Am J Med 2003; 115Suppl. 3A: 150S–6S
Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: Sl–31
Shepherd RW, Wren J, Evans S, et al. Gastroesophageal reflux in children: clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr 1987; 26: 55–60
Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569–72
Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000; 154: 150–4
El-Serag HB, Gilger M, Carter J, et al. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 2004; 99: 806–12
Mallet E, Mouterde O, Dubois F, et al. Use of ranitidine in young infants with gastro-oesophageal reflux. Eur J Clin Pharmacol 1989; 36: 641–2
Goudsouzian NG, Young ET. The efficacy of ranitidine in children. Acta Anaesthesiol Scand 1987; 31: 387–90
Blumer JL, Rothstein FC, Kaplan BS, et al. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr 1985; 107: 301–6
Winnick S, Lucas DO, Hartman AL, et al. How do you improve compliance? Pediatrics 2005; 115: e718–24
Sanz EJ. Concordance and children’s use of medicines. BMJ 2003; 327: 858–60
De Civita M, Dobkin PL. Pediatric adherence as a multidimensional and dynamic construct, involving a triadic partnership. J Pediatr Psychol 2004; 29: 157–69
Gibb DM, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003; 22: 56–62
Gold BD. Review article: epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004; 19Suppl. 1: 22–7
Goresky GV, Finley GA, Bissonnette B, et al. Efficacy, duration, and absorption of a paediatric oral liquid preparation of ranitidine hydrochloride. Can J Anaesth 1992; 39: 791–8
Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5–11 years. Pediatr Drugs 2004; 6: 127–31
Orenstein SR, Blumer JL, Faessel HM, et al. Ranitidine, 75mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002; 16: 899–907
Jack D, Thomas M, Skidmore IF. Ranitidine and paracetamol metabolism [letter]. Lancet 1985; II: 1067
Kim J, Keininger D, Becker S, et al. Simultaneous development of the Pediatric GERD Caregiver Impact Questionnaire (PGCIQ) in American English and American Spanish. Health Qual Life Outcomes 2005; 3: 5
Acknowledgments
The authors thank the staff of Hill Top Research Inc. for conducting the study and Patrice Ferriola for writing and editing assistance in the preparation of the manuscript. Funding for this research was provided by GlaxoSmithKline, the manufacturer of Zantac®. All authors are employees of GlaxoSmithKline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ameen, V.Z., Pobiner, B.F., Giguere, G.C. et al. Ranitidine (Zantac®) Syrup versus Ranitidine Effervescent Tablets (Zantac® EFFERdose®) in Children. Pediatr-Drugs 8, 265–270 (2006). https://doi.org/10.2165/00148581-200608040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00148581-200608040-00005